Okairos AG is a biopharmaceutical company focused on the discovery and development of genetic T-cell vaccines, including hepatitis C virus.
Business Model:
Revenue: $0
Employees: 1-10
Okairos was acquired by
GlaxoSmithKline.
The acquisition happend on 2013-05-29.
Details of the transaction were not public
Address:
City: Basel
State: Basel-Stadt
Zip:
Country: Switzerland
Okairos AG, a bio-pharmaceutical company, focuses on the discovery and development of genetic T-cell vaccines, including hepatitis C virus. The company also provides health and allied services. It has operations in Rome and Naples, Italy. The company is based in Basel, Switzerland. Okairos AG was former subsidiary of Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 3/2007 | Series A | 3 | $9.6M |
BioMedPartners Novartis Venture Fund Life Sciences Partners BioMedPartners Life Sciences Partners BioMedPartners Novartis Venture Fund Life Sciences Partners BioMedPartners Life Sciences Partners |
9/2010 | Series B | 2 | $20.5M |
Versant Ventures Boehringer Ingelheim Venture Fund Boehringer Ingelheim Venture Fund Versant Ventures Versant Ventures Boehringer Ingelheim Venture Fund Boehringer Ingelheim Venture Fund Versant Ventures |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|